Bermekimab Goes to Janssen for up to $1.35b in Deal that Could Shake up Future Hidradenitis Suppurativa & Atopic Dermatitis Market

Bermekimab Goes to Janssen for up to $1.35b in Deal that Could Shake up Future Hidradenitis Suppurativa & Atopic Dermatitis Market

XBiotech’s Bermekimab, a promising experimental drug generating significant interest with Hidradenitis Suppurativa patients in the TrialSite News network, has been sold to Janssen Biotech, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson. Bermekimab is...
Society of Urologic Oncology Trials Consortium (SUO-CTC) Represents Over 200 Urology Investigative Sites

Society of Urologic Oncology Trials Consortium (SUO-CTC) Represents Over 200 Urology Investigative Sites

The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), created, owed and operated by its members, represents a clinical research investigator network over 400 members and more than 200 clinical research sites in the United States and Canada. This...

Pin It on Pinterest